Letters to the EditorThe Other Victims of COVID-19 The Value of Electroconvulsive TherapySagué-Vilavella, Maria MD, MPH; Gil-Badenes, Joaquín MD; Baldaquí Baeza, Núria MD; Madero Gómez, Santiago MD; Pacchiarotti, Isabella MD, PhD; Pons Cabrera, Maria Teresa MD; Valentí Ribas, Marc MD, PhD; Bioque, Miquel MD, PhDAuthor Information Department of Psychiatry and Psychology Institute of Neuroscience Hospital Clínic de Barcelona Barcelona, Catalonia, Spain [email protected] This research did not receive any specific funding. The authors do not report any financial or other relationship relevant to the subject of this article. Some of them, however, do report conflicts of interest not related to this research. M.S.V. has received financial support for education and training from Janssen-Cilag and Lundbeck. J.G.B. has received financial support for traveling and educational activities from Adamed, Italfármaco, Lundbeck, and Janssen. I.P. has received continuing medical education–related honoraria or consulting fees from ADAMED, Janssen-Cilag, and Lundbeck. M.V.R. has received research grants from Eli Lilly & Company and has served as a speaker for Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Cilag, and Lundbeck. M.B. has been a consultant for, received grant/research support and honoraria from, been on the speakers/advisory board of, and received honoraria from talks and/or consultancy of Adamed, Angelini, Ferrer, Janssen-Cilag, Lundbeck, Otsuka, Neuraxpharm, Pfizer and Sanofi. The Journal of ECT: March 2021 - Volume 37 - Issue 1 - p e1-e2 doi: 10.1097/YCT.0000000000000718 Buy Metrics Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.